Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Regeneron Expands Bispecifics, Gene Therapy Programs As Exec Hints At More Deals

Executive Summary

The drug maker reported what it said were encouraging early uptake signs for Eylea HD while also seeking to reassure analysts concerned about its BCMA-directed bispecific’s differentiation.

You may also be interested in...

It’s All About Abecma As 2seventy Sells Off Pipeline To Regeneron In Restructuring

The cell therapy biotech will reduce its headcount from 280 to 65, with most of them – including two execs – going to Regeneron, which is paying just $5m up front to become a cell therapy player.

Formycon And Alvotech Offer Updates On Aflibercept

Biosimilar aflibercept rivals to Eylea are advancing towards approval, with Formycon reporting EMA acceptance of its filing for its FYB203 version and Alvotech disclosing positive trial results for its AVT06 candidate.

Regeneron Releases New Linvoseltamab Analysis As It Inches Toward ASH, Regulatory Filing

The BCMAxCD3-directed bispecific for multiple myeloma is one of the crown jewels of Regeneron’s larger program to develop bispecifics as it diversifies beyond its traditional core franchises.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts